|
Inhibitors of MNK Kinase for Targeted Cancer and CNS Therapeutics.
NU 2015-098 (NU 2015-098, NU 2018-036, NU 2025-036)
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
SHORT DESCRIPTION
MNK kinase inhibitors that reduce cancer cell viability and proliferation and penetrates the brain for potential treatment of glioblastoma and CNS disorders.
BACKGROUND
Leukemia and brain...
Published: 4/29/2026
|
Updated: 4/29/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, AML - Acute myeloid leukemia, ASD - Autism Spectrum Disorder, Bladder cancer, Brain cancer, Breast cancer, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Lung cancer, Neurodegenerative disease, Pancreatic cancer, Prostate cancer, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets
SHORT DESCRIPTION
A targeted-protein degradation platform for intracellular targets, addressing resistant oncogenic and neurodegenerative targets.
INVENTORS
Shana Kelley*
Weinberg College of Arts & Sciences, Department of Chemistry
Yi Li
* Principal Investigator
NU 2025-050
IP STATUS
PCT...
Published: 4/27/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, Biologic, Biomolecular condensates, Cancer/Oncology, Drug delivery, Nanoparticle, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Platform technology, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 4/14/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081
INVENTORS
Sarki Abdulkadir (PI)*
Northwestern University Feinberg School of Medicine, Department of Urology
Gary Schiltz (PI)*
Weinberg College of Arts and Sciences, Department of Chemistry
SHORT DESCRIPTION
A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate...
Published: 4/7/2026
|
Updated: 2/3/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
IDO-PROTACs for Improving the Anti-Cancer Immune Response
NU 2020-137
INVENTORS
Derek Wainwright*
Gary Schiltz
SHORT DESCRIPTION
IDO-PROTAC that target immunosuppressive IDO activity via degradation
ABSTRACT
The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy, chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...
Published: 3/3/2026
|
Updated: 5/27/2022
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Brain cancer, Cancer/Oncology, Colon cancer, Endometrial cancer, Immunotherapy, Pancreatic cancer, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|